Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

FDA seizes hundreds of fake Ozempic units from US supply after Novo Nordisk alerts regulators to counterfeit semaglutide ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.